RESPONSE: re: preclinical and clinical development of cyclin-dependent kinase modulators
Senderowicz
AM
A. M. Senderowicz, Molecular Therapeutics Unit, Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, Bethesda, MD.
Sausville
EA